drugset / Trial / NCT03362242

Study of ARO-AAT in Normal Adult Volunteers

NCT03362242 ↗

Phase 1 Completed 45 enrolled Arrowhead Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-AAT in healthy adult volunteers.

Timeline

Start
2018-03-12
Primary completion
2018-10-23
Completion
2020-03-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARO-AAT Unknown — Subcutaneous